Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biohaven Ltd (NY: BHVN )

44.77 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Apr 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 44.77
Bid (Size) 40.00 (1)
Ask (Size) 47.97 (1)
Prev. Close 44.77
Today's Range 44.77 - 44.77
52wk Range 12.35 - 62.21
Shares Outstanding 65,401,228
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic... 
Via Benzinga
Why Is Obesity Drug Developer Altimmune Stock Trading Lower On Wednesday?
Latest findings on Altimmune's pemvidutide on body composition: lean mass preservation, significant weight loss from adipose tissue, and results in obesity and Metabolic dysfunction-associated... 
Via Benzinga

Performance

YTD
+6.77%
+6.77%
1 Month
-21.10%
-21.10%
3 Month
+0.38%
+0.38%
6 Month
+63.45%
+63.45%
1 Year
+213.74%
+213.74%

More News

Read More
Obesity Drug Landscape Has A Contender From Biohaven, CEO Highlights Different Approach Amid Stiff Competition From Novo Nordisk, Eli Lilly
Via Benzinga
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) is a Stock Spotlight on 3/8
Via Investor Brand Network
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) is a Stock Spotlight on 3/4
Via Investor Brand Network
Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On.
Via Investor's Business Daily
This Analyst Is Bullish On Biohaven's Approach in Neuro-Psych Space
Via Benzinga
Stocks to Watch: 3 Companies Working on Next-Gen Weight Loss Drugs
Via InvestorPlace
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) is a Stock Spotlight on 1/5
Via Investor Brand Network
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Via Investor's Business Daily
FedEx Posts Downbeat Earnings, Joins Steelcase, argenx And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
Based on good technical signals, BIOHAVEN LTD is potentially setting up for a breakout.
Via Chartmill
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) Sets New 52-Week High in Monday Session
Via Investor Brand Network
Biohaven Ltd. (NYSE: BHVN) Records 52-Week High Thursday Morning
Via Investor Brand Network
Stock Market Rally Attempt Underway; Micron, Nike, Amazon, Meta In Focus: Weekly Review
Via Investor's Business Daily
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
What's Going On Pfizer's Subsidiary Biohaven Stock?
Via Benzinga
Why Sharps Technology Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Biohaven, Yet Another Argenx Rival In Autoimmune Drugs, Just Rocketed 29%
Via Investor's Business Daily
Why Biohaven Stock Is Skyrocketing Today
Via The Motley Fool
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) Leading the Way in Wednesday Trading Based on Percentage Gain
Via Investor Brand Network
MillerKnoll, Hayward Holdings, Ginkgo Bioworks And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Topics Stocks
Exposures US Equities
US Stocks Open Higher; Costco Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.